EHA 2019 | AML: ivosidenib is coming

Paresh Vyas

Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, discusses the use of ivosidenib in the treatment of acute myeloid leukemia (AML) and myelodysplasia for patients with a specific genetic abnormality either alone or as part of combination therapy. Speaking at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands, Prof. Vyas also comments that ivosidenib is available in the USA, is being considered by the European Medicines Agency (EMA) and is available in the UK via clinical trials.

Share this video  
Similar topics